Related Experiment Video
Updated: Jul 20, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Budesonide for ulcerative colitis.
1Department of Gastroenterology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
Revista Espanola De Enfermedades Digestivas
|September 2, 2006
Summary
Budesonide, a potent corticosteroid, shows promise for ulcerative colitis (UC) treatment. Further controlled trials are needed to confirm the efficacy and safety of oral budesonide for inflammatory bowel disease (IBD).
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Budesonide is a locally acting glucocorticosteroid with significant first-pass liver metabolism.
- Controlled-release oral budesonide has demonstrated efficacy comparable to prednisolone in Crohn's disease (CD) without significant cortisol suppression.
- While extensively studied for CD, research on oral budesonide for ulcerative colitis (UC) is limited.
Purpose of the Study:
- To review existing literature on oral and topical budesonide for ulcerative colitis (UC) treatment.
- To assess the current evidence base for budesonide's efficacy and safety in UC.
- To identify the need for further research in this area.
Main Methods:
- Systematic review of published studies on oral and topical budesonide formulations.
- Analysis of clinical trial data and observational studies.
- Evaluation of efficacy and safety profiles.
Main Results:
- Budesonide has shown success as a controlled-release formulation in managing inflammatory bowel disease (IBD).
- Studies indicate budesonide's efficacy in Crohn's disease (CD) have led to its registration for this condition.
- Evidence for oral budesonide in ulcerative colitis (UC) is currently scarce.
Conclusions:
- Controlled trials are recommended to establish evidence-based efficacy and safety of oral budesonide for ulcerative colitis (UC).
- Further research is crucial to determine the full therapeutic potential of budesonide in UC patients.
- This could lead to improved treatment options for this form of inflammatory bowel disease (IBD).
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...